Targeting S-adenosylmethionine biosynthesis with a novel allosteric inhibitor of Mat2A

Nature Chemical Biology

Volumn 13, Issue 7, 2017, Pages 785-792

  Quinlan, Casey L ^a   Kaiser, Stephen E ^a   Bolaños, Ben ^a   Nowlin, Dawn ^a   Grantner, Rita ^a   Karlicek Bryant, Shannon ^a   Feng, Jun Li ^a   Jenkinson, Stephen ^a   Freeman Cook, Kevin ^a   Dann, Stephen G ^a   Wang, Xiaoli ^a   Wells, Peter A ^a   Fantin, Valeria R ^b   Stewart, Al E ^a   Grant, Stephan K ^a  

^a PFIZER INC   (United States)

^b ORIC Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHIONINE; METHIONINE ADENOSYLTRANSFERASE; METHIONINE ADENOSYLTRANSFERASE 2A; S ADENOSYLMETHIONINE; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; MAT2A PROTEIN, HUMAN; PF-9366; QUINOLINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ALLOSTERIC SITE; ALLOSTERISM; ARTICLE; BINDING SITE; BIOSYNTHESIS; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME METABOLISM; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HUMAN; ISOLATION AND PURIFICATION; KINETICS; METABOLISM; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ALLOSTERIC SITE; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KINETICS; METHIONINE ADENOSYLTRANSFERASE; QUINOLINES; S-ADENOSYLMETHIONINE; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 85021151485     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.2384     Document Type: Article

References (43)

1. Timp, W. & Feinberg, A.P. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat. Rev. Cancer 13, 497-510 (2013).
2. Lu, S.C. & Mato, J.M. S-adenosylmethionine in liver health, injury, and cancer. Physiol. Rev. 92, 1515-1542 (2012).
3. Halim, A.B., LeGros, L., Geller, A. & Kotb, M. Expression and functional interaction of the catalytic and regulatory subunits of human methionine adenosyltransferase in mammalian cells. J. Biol. Chem. 274, 29720-29725 (1999).
4. Kotb, M. & Kredich, N.M. Regulation of human lymphocyte S-adenosylmethionine synthetase by product inhibition. Biochim. Biophys. Acta 1039, 253-260 (1990).
5. LeGros, H.L. Jr., Geller, A.M. & Kotb, M. Differential regulation of methionine adenosyltransferase in superantigen and mitogen stimulated human T lymphocytes. J. Biol. Chem. 272, 16040-16047 (1997).
6. Nordgren, K.K. et al. Methionine adenosyltransferase 2A/2B and methylation: gene sequence variation and functional genomics. Drug Metab. Dispos. 39, 2135-2147 (2011).
7. Cai, J., Mao, Z., Hwang, J.J. & Lu, S.C. Differential expression of methionine adenosyltransferase genes influences the rate of growth of human hepatocellular carcinoma cells. Cancer Res. 58, 1444-1450 (1998).
8. Jani, T.S. et al. Inhibition of methionine adenosyltransferase II induces FasL expression, Fas-DISC formation and caspase-8-dependent apoptotic death in T leukemic cells. Cell Res. 19, 358-369 (2009).
9. Cai, J., Sun, W.M., Hwang, J.J., Stain, S.C. & Lu, S.C. Changes in S-adenosylmethionine synthetase in human liver cancer: molecular characterization and significance. Hepatology 24, 1090-1097 (1996).
10. Frau, M., Feo, F. & Pascale, R.M. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis. J. Hepatol. 59, 830-841 (2013).
11. Martínez-Chantar, M.L. et al. Methionine adenosyltransferase II β subunit gene expression provides a proliferative advantage in human hepatoma. Gastroenterology 124, 940-948 (2003).
12. Chen, H. et al. Role of methionine adenosyltransferase 2A and S-adenosylmethionine in mitogen-induced growth of human colon cancer cells. Gastroenterology 133, 207-218 (2007).
13. Liu, Q. et al. Silencing MAT2A gene by RNA interference inhibited cell growth and induced apoptosis in human hepatoma cells. Hepatol. Res. 37, 376-388 (2007).
14. Lombardini, J.B., Coulter, A.W. & Talalay, P. Analogues of methionine as substrates and inhibitors of the methionine adenosyltransferase reaction. Deductions concerning the conformation of methionine. Mol. Pharmacol. 6, 481-499 (1970).
15. Lombardini, J.B. & Sufrin, J.R. Chemotherapeutic potential of methionine analogue inhibitors of tumor-derived methionine adenosyltransferases. Biochem. Pharmacol. 32, 489-495 (1983).
16. Sviripa, V.M. et al. 2′,6′-Dihalostyrylanilines, pyridines, and pyrimidines for the inhibition of the catalytic subunit of methionine S-adenosyltransferase-2. J. Med. Chem. 57, 6083-6091 (2014).
17. Attia, R.R. et al. Selective targeting of leukemic cell growth in vivo and in vitro using a gene silencing approach to diminish S-adenosylmethionine synthesis. J. Biol. Chem. 283, 30788-30795 (2008).
18. Hester, J.B. Jr., Rudzik, A.D. & VonVoigtlander, P.F. 1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity. J. Med. Chem. 23, 392-402 (1980).
19. Shafqat, N. et al. Insight into S-adenosylmethionine biosynthesis from the crystal structures of the human methionine adenosyltransferase catalytic and regulatory subunits. Biochem. J. 452, 27-36 (2013).
20. Murray, B. et al. Structure and function study of the complex that synthesizes S-adenosylmethionine. IUCrJ 1, 240-249 (2014).
21. Marjon, K. et al. MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis. Cell Rep. 15, 574-587 (2016).
22. Murray, B. et al. Crystallography captures catalytic steps in human methionine adenosyltransferase enzymes. Proc. Natl. Acad. Sci. USA 113, 2104-2109 (2016).
23. Finkelstein, J.D. Methionine metabolism in mammals. J. Nutr. Biochem. 1, 228-237 (1990).
24. del Pino, M.M.S., Corrales, F.J. & Mato, J.M. Hysteretic behavior of methionine adenosyltransferase III. Methionine switches between two conformations of the enzyme with different specific activity. J. Biol. Chem. 275, 23476-23482 (2000).
25. Orenstein, J.M. & Marsh, W.H. Incorporation in vivo of methionine and ethionine into and the methylation and ethylation of rat liver nuclear proteins. Biochem. J. 109, 697-699 (1968).
26. Liu, Q. et al. Hypoxia induces genomic DNA demethylation through the activation of HIF-1α and transcriptional upregulation of MAT2A in hepatoma cells. Mol. Cancer Ther. 10, 1113-1123 (2011).
27. Panayiotidis, M.I. et al. Activation of a novel isoform of methionine adenosyl transferase 2A and increased S-adenosylmethionine turnover in lung epithelial cells exposed to hyperoxia. Free Radic. Biol. Med. 40, 348-358 (2006).
28. Ramani, K. et al. Leptin's mitogenic effect in human liver cancer cells requires induction of both methionine adenosyltransferase 2A and 2β. Hepatology 47, 521-531 (2008).
29. Wang, X. et al. Expression of methionine adenosyltransferase 2A in renal cell carcinomas and potential mechanism for kidney carcinogenesis. BMC Cancer 14, 196 (2014).
30. Yang, H., Li, T.W., Peng, J., Mato, J.M. & Lu, S.C. Insulin-like growth factor 1 activates methionine adenosyltransferase 2A transcription by multiple pathways in human colon cancer cells. Biochem. J. 436, 507-516 (2011).
31. Zhang, T. et al. Overexpression of methionine adenosyltransferase II alpha (MAT2A) in gastric cancer and induction of cell cycle arrest and apoptosis in SGC-7901 cells by shRNA-mediated silencing of MAT2A gene. Acta Histochem. 115, 48-55 (2013).
32. Mavrakis, K.J. et al. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5. Science 351, 1208-1213 (2016).
33. Kornev, A.P. & Taylor, S.S. Dynamics-driven allostery in protein kinases. Trends Biochem. Sci. 40, 628-647 (2015).
34. Süel, G.M., Lockless, S.W., Wall, M.A. & Ranganathan, R. Evolutionarily conserved networks of residues mediate allosteric communication in proteins. Nat. Struct. Biol. 10, 59-69 (2003).
35. Tomasi, M.L., Li, T.W., Li, M., Mato, J.M. & Lu, S.C. Inhibition of human methionine adenosyltransferase 1A transcription by coding region methylation. J. Cell. Physiol. 227, 1583-1591 (2012).
36. Yang, H. et al. Role of promoter methylation in increased methionine adenosyltransferase 2A expression in human liver cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 280, G184-G190 (2001).
37. Maegley, K.A., Krivacic, C., Bingham, P., Liu, W. & Brooun, A. Comparison of a high-throughput mass spectrometry method and radioactive filter binding to assay the protein methyltransferase PRMT5. Assay Drug Dev. Technol. 13, 235-240 (2015).
38. Wiseman, T., Williston, S., Brandts, J.F. & Lin, L.N. Rapid measurement of binding constants and heats of binding using a new titration calorimeter. Anal. Biochem. 179, 131-137 (1989).
39. Vonrhein, C. et al. Data processing and analysis with the autoPROC toolbox. Acta Crystallogr. D Biol. Crystallogr. 67, 293-302 (2011).
40. McCoy, A.J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
41. Emsley, P., Lohkamp, B., Scott, W.G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010).
42. Adams, P.D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213-221 (2010).
43. Burke, J.E., Perisic, O., Masson, G.R., Vadas, O. & Williams, R.L. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA). Proc. Natl. Acad. Sci. USA 109, 15259-15264 (2012).